Résumé
Avec l’augmentation du nombre d’agents biologiques potentiellement indiqués dans le traitement de la polyarthrite rhumatoide (PR) est apparu un nouveau problème: celui du choix d’une biothérapie de la PR. Celui-ci ne doit pas etre cause d’angoisse pour le thérapeute, mais etre considéré comme la conséquence d’un plus grand nombre d’options possibles, et une chance pour le patient et le médecin.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Fautrel B, Guillemin F, Meyer O et al. (2009) Choice of second-hne disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clinical practice based on rheumatologists’ preferences. Arthritis Rheum. 61:425–34
Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. (2007) Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66:1356–62
Purst DE, Keystone EC, Kirkham B et al. (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67(Suppl 3): iii2–25
Kievit W, Adang EM, Fransen J et al. (2008) The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 67:1229–34
Pan SM, Dehler S, Ciurea A et al. (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61: 560–568
Hetland ML, Christensen IJ, Tarp U et al. (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide danish DANBIO registry. Arthritis Rheum 62: 22–32
Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther U Suppl 1:S1
Finckh A, Ciurea A, Brulhart L et al. (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417–23
Schiff M, Keiserman M, Codding C et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase 111, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoidarthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–103
Gartlehner G, Hansen RA, lonas BL et al. (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. 1 Rheumatol 33: 2398–408
Buch MH, Bingham SJ, Seto Y et al. (2004) Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50: 725–8
Cohen SB, Emery P, Greenwald MW et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase 111 trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–806
Genovese MC, Becker JC, Schiff M. et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–23
Emery P, Keystone E, Tony HP et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–23
Castro-Rueda H, Kavanaugh A (2008) Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 20: 314–9
Westhovens R, Robles M, Ximenes AC et al. (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68:1870–7
Iones G, Sebba A, Gu J et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 69: 88–96
Fautrel B, Pham T, Mouterde G et al. (2007) Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 74: 627–37
Atzeni F, Antivalle M, Pallavicini FB et al. (2009) Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 8:431–7
Rights and permissions
Copyright information
© 2011 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Wendling, D. (2011). Les critères de choix d’une biothérapie de la polyarthrite rhumatoïde. In: Biothèrapies en rhumatologie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0124-7_8
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0124-7_8
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0123-0
Online ISBN: 978-2-8178-0124-7